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Abstract: HLA DQA1*05 and DQB1*02 alleles encoding the DQ2.5 molecule and HLA DQA1*03
and DQB1*03 alleles encoding DQ8 molecules are strongly associated with celiac disease (CD) and
type 1 diabetes (T1D), two common autoimmune diseases (AD). We previously demonstrated that
DQ2.5 genes showed a higher expression with respect to non-CD associated alleles in heterozygous
DQ2.5 positive (HLA DR1/DR3) antigen presenting cells (APC) of CD patients. This differential
expression affected the level of the encoded DQ2.5 molecules on the APC surface and established
the strength of gluten-specific CD4+ T cells response. Here, we expanded the expression analysis of
risk alleles in patients affected by T1D or by T1D and CD comorbidity. In agreement with previous
findings, we found that DQ2.5 and DQ8 risk alleles are more expressed than non-associated alleles
also in T1D patients and favor the self-antigen presentation. To investigate the mechanism causing
the high expression of risk alleles, we focused on HLA DQA1*05 and DQB1*02 alleles and, by ectopic
expression of a single mRNA, we modified the quantitative equilibrium among the two transcripts.
After transfection of DR7/DR14 B-LCL with HLA-DQA1*05 cDNA, we observed an overexpression
of the endogenous DQB1*02 allele. The DQ2.5 heterodimer synthesized was functional and able to
present gluten antigens to cognate CD4+ T cells. Our results indicated that the high expression of
alpha and beta transcripts, encoding for the DQ2.5 heterodimeric molecules, was strictly coordinated
by a mechanism acting at a transcriptional level. These findings suggested that, in addition to the
predisposing HLA-DQ genotype, also the expression of risk alleles contributed to the establishment
of autoimmunity.
Keywords: autoimmunity; risk genes; expression; regulation
1. Introduction
The human leukocyte antigen (HLA) class II heterodimeric molecules, composed by the alpha
and beta chains, are encoded by many different alleles, which generate the high polymorphism
characteristic of this locus. The genes encoding DR and DQ isotypes are the main risk factors associated
with several autoimmune diseases. Type 1 diabetes (T1D) and celiac disease (CD) are autoimmune
disorders, affecting between 0.5% and 1% of the general population. Very frequently, these two diseases
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co-occur in families, and approximately 4–9% of patients with T1D also have CD, while patients with
CD are at increased risk of developing T1D [1]. CD and T1D share immunopathogenic mechanisms,
although the autoreactive T cells and autoantibodies are directed against different autoantigens, such
as insulin, GADA65, and IA-2 in T1D [2] and tissue transglutaminase in CD [3]. The HLA-DRB1,
HLA-DQA1, and HLA-DQB1 genes display a major component of familial clustering in both T1D
and CD. Subjects at high risk to develop T1D carry either DQ2.5 haplotype, encoded by DQA1*05:01
and DQB1*02:01 or DQ8 haplotype, encoded by DQA1*03:01 and DQB1*03:02 [4]., whereas the
most prominent association of CD is with HLA-DQ2.5 molecules [5]. The alleles encoding DQ2.5
molecule are in linkage disequilibrium (LD) with HLA-DRB1*03, while the DQ8 alleles are in LD with
HLA-DRB1*04. More specifically, considering the subtype specificity, the DRB1*03:01 is found coupled
to DQA1*05:01 and DQB1*02:01 almost exclusively, thus creating the haplotype called “DR3”, while
DRB1*04:01 is found in LD with DQA1*03:01 but can have either DQB1*03:01 or DQB1*03:02 included
in the haplotype. Both are referred to as “DR4” haplotypes, although that carrying the DQB1*03:02
allele (DQ8 haplotype) predisposes to disease and that with DQB1*03:01 allele (DQ7 haplotype) is
protective [4,5]. T1D risk depends not only on the haplotypic context but also on the genotypic assets
of the risk alleles. In fact, the highest risk is conferred by DR3/DR4 heterozygous genotype. The
contribution of DR3/DR4 is higher than the sum of the individual DR3 and DR4 haplotypes. This
group comprised T1D subjects carrying DRB1*03:01-DQA1*05:01-DQB1*02 on one chromosome and
DRB1*04:01-DQA1*03:01-DQB1*03:02 on the other chromosome. One hypothesis for the increased
risk is the putative presence of DQ heterodimers encoded by alleles in trans, in addition to the DQ
molecules encoded by alleles in cis, on the cell surface of immune cells [6,7].
We have previously demonstrated [8] that APCs from celiac patients, carrying the DR3-DQ2.5
haplotype in homozygosis (DR3/DR3) or in heterozygosis (DR1/DR3) have a comparable ability to
stimulate the CD4+ T cell activation and proliferation when challenged with an equivalent amount of
gluten antigen. This finding is a consequence of the differential expression of DQA1*05 and DQB1*02
alleles compared to non-CD-associated ones, affecting the DQα1*05 and DQβ1*02 chain amount and
the HLA-DQ2.5 surface heterodimers density. In the present work, we measured the expression of
DQ2.5 and DQ8 risk genes in APC from patients affected by T1D and from patients affected by T1D
and CD comorbidity, that could be relevant in the activation of antigen specific CD4 lymphocytes.
Previous papers from our lab have demonstrated the stoichiometric balance of two messengers
encoding alpha and beta protein chains, by a mechanism coordinating the transcription and the mRNA
processing. A ribonucleoprotein complex, binding the 5’UTR and 3′UTR of HLA class II transcripts,
regulates the nucleus-cytoplasm export and degradation of these mRNA [9,10]. Moreover, it has
been demonstrated that the ectopic over-expression of the DRB1 gene determines an increase of the
endogenous DRA mRNA in non-professional APC, such as melanoma M14 cell line. In order to
investigate the mechanism determining the high and the coordinated expression of DQA1*05 and
DQB1*02 risk alleles, we have set up experiments aimed to perturb the stoichiometric balance of two
mRNA and to assess the functionality of resulting heterodimers in the antigen presentation.
2. Materials and Methods
2.1. Patients Enrollment and Selection of Antigen Presenting Cells
Type 1 diabetes patients were enrolled at the Department of Pediatrics, University Hospital
“Federico II” of Naples, where they are regularly followed up. Patients or their parents, in the case
of children under 12 years old, were informed about the objective of the study and provided written
informed consent in accordance with the ethical standards of the institutional, the national research
committee, and in accordance with the 1964 Helsinki declaration and its later ethical amendments.
Peripheral blood mononuclear cells (PBMC) were isolated from blood samples of patients and
healthy donors by Ficoll-Paque gradient separation. PBMC were used to prepare genomic DNA
and total RNA. B lymphoblastoid cell lines (B-LCL), used as APCs, were obtained, as previously
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reported. All subjects enrolled were genotyped for DQA1 and DQB1 by using AllSet Gold SSP
HLA-DQ Low Res kit (Thermo Fisher Scientific, Monza, Italy) and the genotypes are indicated in
Table 1. In the functional test with T cells and in the nucleofection experiments we used DR1/DR3
positive B-LCL (B-LCL#5) from CD patient carrying DQA1*05-DQA1*01/DQB1*02-DQB1*05 genotype
that was previously described [8] and DR7/DR14 positive B-LCL from a healthy donor carrying
DQA1*02-DQA1*01/DQB1*02-DQB1*05 genotype.
Table 1. HLA-DQ and HLA-DR genotype and phenotype of T1D patients enrolled in the study.
Code Cells a Diagnosis DQA1Genotype
DQB1
Genotype
DQ
Phenotype
DR
Phenotype
§1 B-LCL T1D *03/*05 *02/*03 DQ2.5/DQ8 DR3/DR4
§2 B-LCL T1D *03/*05 *02/*02 DQ2.5/DQ2.3 DR3/DR9
§3 B-LCL T1D *05/*05 *02/*02 DQ2.5/DQ2.5 DR3/DR3
§4 B-LCL T1D with CD *03/*05 *02/*03 DQ2.5/DQ8 DR3/DR4
§5 B-LCL T1D with CD *01/*03 *05/*03 DQ8/DQ5 DR4/DR16
§6 B-LCL T1D with CD *01/*05 *02/*05 DQ2.5/DQ5 DR1/DR3
§7 B-LCL T1D with CD *02/*05 *02/*02 DQ2.5/DQ2.2 DR3/DR7
§8 B-LCL T1D with CD *05/*05 *02/*02 DQ2.5/DQ2.5 DR3/DR3
§9 PBMC T1D *01/*05 *02/*05 DQ2.5/DQ5 DR1/DR3
§10 PBMC T1D *01/*05 *02/*06 DQ2.5/DQ6 DR3/DR15
§11 PBMC T1D *01/*05 *02/*05 DQ2.5/DQ5 DR1/DR3
§12 PBMC T1D *01/*03 *03/*05 DQ8/DQ5 DR4/DR1
§13 PBMC T1D *03/*05 *02/*03 DQ2.5/DQ8 DR3/DR4
§14 PBMC T1D *03/*05 *02/*03 DQ2.5/DQ8 DR3/DR4
§15 PBMC T1D *01/*03 *03/*05 DQ8/DQ5 DR4/DR1
§16 PBMC T1D *05/*05 *02/*03 DQ2.5/DQ7 DR3/DR5
§17 PBMC T1D *01/*05 *02/*05 DQ2.5/DQ5 DR3/DR1
§18 PBMC T1D *03/*03 *03/*03 DQ8/DQ8 DR4/DR4
§19 PBMC T1D *01/*03 *03/*05 DQ8/DQ5 DR4/DR1
§20 PBMC T1D *03/*03 *03/*03 DQ8/DQ8 DR4/DR4
§21 PBMC T1D *01/*03 *03/*05 DQ8/DQ5 DR4/DR1
a the immune cell source for HLA genotyping.
2.2. Monoclonal Antibodies and Flow Cytometry Analysis
B-LCLs were harvested when they were at sub-confluence and were suspended at 106 cells/mL in
ice-cold PBS, 10% FCS and 1% NaN3. Then, 100 µl of cell suspension was plated in a 96 V-bottom plate
and labeled with 10 µg/mL of primary or isotypes control monoclonal antibodies, or with 10µl of the
hybridoma supernatant, previously titrated. The cells were incubated at 4 ◦C in the dark for 30 min,
washed and thereafter labeled with secondary antibodies at a final concentration of 1 µg/mL in 3%
BSA/PBS for an additional 30 min at 4 ◦C in the dark. The primary monoclonal antibodies used to
reveal the cell surface HLA DQ expression were: SFR20-DQa5, a rat anti-HLADQA1*05 purified from
a hybridoma supernatant, kindly provided by Prof Radka [11]; 2.12E11, a murine anti-HLA-DQB1*02,
kindly provided by Prof L. Sollid [12]. Fluorochrome conjugated anti-rat IgG(-PE) and anti-mouse IgG
(FITC) were used as secondary antibodies. All phenotypes were analyzed with FACSCanto II system
and elaborated using the DIVA software (BD Biosciences, Milan, Italy).
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2.3. cDNA Cloning and B-LCL Nucleofection
The full-length DQA1*05 and DQB1*02 cDNA were prepared using retrotranscribed RNA from
B-LCL of homozygous DR3/DR3 positive CD patient (B-LCL#1), previously described [8]. By specific
primers, we cloned both cDNA in pcDNA3 vector and named the constructs pDQA105 and pDQB102.
Using pDQA105 as a template, we cloned the cDNA deleted of 3′UTR (pDQA105∆). The correct
cloning was assessed by sequencing (Eurofins, Munchen, Germany). We transfected DR1/DR3 B-LCL#5
with three constructs and DR7/DR14 B-LCL with pDQA105 by nucleofection using Amaxa Cell line
Nucleofector kit V (Lonza, Euroclone, Milan Italy). Cells were harvested after 24 h for the RNA
preparation and functional test and after 48 h for flow cytometry experiments.
2.4. RNA Quantization
Total RNA was prepared with the Aurum™ Total RNA kit (BIORAD, Milan, Italy), and 0.5 µg
of RNA was used for reverse transcriptase reactions, performed using an iScript™ cDNA Synthesis
kit (BIORAD). The number of specific transcripts was measured by qPCR using the Quanti Tect
SYBR Green PCR Kit (BIORAD) through the DNA Engine Opticon Real-Time PCR Detection System
(BIORAD). Each reaction was run in triplicates in the presence of 0.2 mM primers synthesized by
Eurofins, and each experiment was performed four times. The primer sequences are reported in
Table 2. The relative amount of specific transcripts was calculated by the comparative cycle threshold
method [13] and β-actin transcript was used for normalization.
Table 2. Primers used for qPCR.
Gene Primers Sequences 5′ → 3′
β-Actin ACT-FACT-R
TCATGAAGTGTGACGTTGACA
CCTAGAAGCATTTGCGGTGCAC
HLA-DQA1*01 DQA1*01-FDQA1*R
CGGTGGCCTGAGTTCAGCAA
GGAGACTTGGAAAACACTGTGACC
HLA-DQA1*02 DQA1*02-FDQA1*R
AAGTTGCCTCTGTTCCACAGAC
GGAGACTTGGAAAACACTGTGACC
HLA-DQA1*03 DQA1*03-FDQA1*R
CTCTGTTCCGCAGATTTAGAAGA
GGAGACTTGGAAAACACTGTGACC
HLA-DQA1*05 DQA1*05-FDQA1*R
CTCTGTTCCGCAGATTTAGAAGA
GGAGACTTGGAAAACACTGTGACC
HLA-DQB1*02 DQB1*02-F DQB1*R TCTTGTGAGCAGAAGCATCTCAGGATCTGGAAGGTCCAGT
HLA-DQB1*03 DQB1*03-F DQB1*R CGGAGTTGGACACGGTGTGCCAGGATCTGGAAGGTCCAGT
HLA-DQB1*05 DQB1*05DQB1*R
ACAACTACGAGGTGGCGTACC
CAGGATCTGGAAGGTCCAGT
HLA-DQB1*06 DQB1*06-FDQB1*R
CAGATCAAAGTCCGGTGGTTTC
CAGGATCTGGAAGGTCCAGT
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The newly synthesized RNA transcripts were captured by Click-iT Nascent RNA Capture Kit
(ThermoFisher), according to manufacturer’s instructions. Briefly, B-LCLs, seeded at 50% confluency,
were labeled with 0.2 mM ethynyl uridine (EU) and incubated at 37 ◦C for 16 h. Total RNA was prepared
with TRIzol reagent (Life Technologies, Thermo Fisher Scientific, Monza, Italy). The EU-labeled RNAs
were biotinylated with 0.5 mM biotin azide in Click-iT reaction buffer (Thermo Fisher Scientific, Monza,
Italy). The biotinylated RNAs were precipitated and resuspended in distilled water. Purified RNA
(0.5 µg) was bound to 25 µL of Dynabeads MyOne Streptavidin T1 magnetic beads in Click-iT RNA
binding buffer. The RNA captured on the beads was used as template for cDNA synthesis. Reverse
transcription was performed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen, Thermo
Fisher Scientific, Monza, Italy) following the manufacturer’s instructions. The number of specific
transcripts was measured by qPCR using SsoAdvanced SYBR Green PCR Kit (BIORAD). The apparatus
and primers used were the same as described above.
2.5. T Cell Functional Assay
A gliadin-reactive T cell line (TCL) was previously established from the jejunal biopsies of a
DR3/DR3 homozygous CD patient in disease remission. The TCL was obtained by stimulating
intestinal cells with irradiated autologous PBMC (1.5 × 106) and gliadin peptide and expanded by cyclic
stimulations with allogenic PBMC and phytohemagglutinin (PHA, 0.5 µg/mL) in complete medium
(X-Vivo 15 medium supplemented with 5% AB-pooled human serum and antibiotics, Lonza). Cells
were fed by adding IL-2 (50 UI/mL, R&D System) every 3 days. This TCL was reactive to DQ2.5-glia-γ1
peptide (PQQPQQSFPQQQQPA) [14]. When in resting phase, T cells (3 × 104) were co-incubated
with indicated B-LCL (1 × 105) pulsed with DQ2.5-glia-γ1 peptide at concentration 0.1 and 1 µM.
In some experiments B-LCL transfected with a pDQA105 construct or with pcDNA (empty vector)
were used. Cell supernatants (50 µL) were collected after 48 h for the evaluation of INF-γ production,
using standard sandwich ELISA procedure. The DQ2.5-glia-γ1 peptide was provided by CASLO ApS,
(Kongens Lyngby, Denmark).
2.6. Statistical Analysis
All results are shown as the mean of at least three independent experiments. Statistical analysis
was performed using the unpaired Student’s t-test with a two-tailed distribution. A p-value less than
0.05 was considered significant.
3. Results
3.1. The DQA1*03 and DQB1*03 mRNA Associated with T1D Risk Were More Abundant than the mRNA of
Non-T1D Related Alleles
We genotyped the DNA of B-LCL and PBMC from patients affected by T1D alone or by T1D
and CD comorbidity in order to identify the HLA-DQ genes (Table 1). The HLA-DR phenotype was
designed by LD. We measured, by qPCR, the amount of DQA1*03, DQA1*05, DQB1*03, and DQB1*02
mRNA with respect to transcripts of alleles not associated with diseases. A value of 100% of mRNA
amount was assigned when DQA1*05 (patients §3, §8), DQA1*03 (patients §18 and §20), DQB1*02
(patients §2, §3, §7, §8) and DQB1*03 (patients §18, §20) alleles were in homozygosis. For patients DQA1
and DQB1 heterozygous, the mRNA amount was expressed as a percentage of the total messenger of
the gene.
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Our results demonstrated that in heterozygous B-LCL, the amount of DQA1*05 (patients §6, §7)
and DQA1*03 (patient §5) mRNA was higher respect to DQA1*01 (patients §5, §6) and DQA1*02
(patient §7) mRNA, as showed in Figure 1A. Similar results were obtained in heterozygous PBMC,
in which either DQA1*05 (patients §9, §10, §11, §17) and DQA1*03 (patients §12, §15, §19, §21)
mRNA are more abundant than DQA1*01 transcript (Figure 1C). Moreover, either B-LCL (patients
§1, §4, Figure 1A) and PBMC (patients §13, §14, Figure 1C) carrying DQ2.5/DQ8 genotypes showed a
comparable amount of DQA1*03 and DQA1*05 mRNA, with exception of B-LCL §2 in which DQA1*05
was more abundant than DQA1*03 (Figure 1A). Similarly, we demonstrated that DQB1 risk alleles
were more expressed with respect to the alleles non-T1D associated. The heterozygous B-LCL of
patients §5 and §6, carrying DQB1*03 or DQB1*02, respectively, showed mRNA amount higher than
DQB1*05 (Figure 1B), as well as the heterozygous PBMC, in which DQB1*02 allele (patients §9, §10, §11,
§17) displayed a quantity of transcript greater than non-predisposing alleles (DQB1*05 and DQB1*06,
Figure 1D). Finally, PBMC §12, §15, §19, and §21 (Figure 1D) expressed a higher level of DQB1*03
mRNA with respect to DQB1*05 mRNA, with the exception of PBMC §16 (Figure 1D) that showed a
lower amount of DQB1*03 mRNA, in comparison to DQB1*02. Finally, the B-LCL of patients §1 and
§4 (Figure 1B) and PBMC of patients §13 and §14, characterized by DQ2.5/DQ8 genotypes, showed
a comparable amount of DQB1*03 and DQB1*02 mRNA (Figure 1D). We calculated the significance
among the expression values of two alleles for each patient and for the group carrying the same alleles
(Figure 1). The fold change (FC) of the expression value for each patient were more clearly reported
in Table 3. Overall, these results demonstrated that disease predisposing alleles are, surprisingly,
expressed at higher levels than non-associated alleles in all heterozygous APC. When DQA1*05 and
DQB1*03 risk alleles, as well as DQB1*02 and DQB1*03, are in the same DQ2.5/DQ8 genotype, the cells
expressed equal amounts of mRNA in all determinations done.
Table 3. DQA1 and DQB1 mRNA fold change in different APC.
Cells Patients mRNA Alleles FoldChange Cells Patients mRNA Alleles
Fold
Change
B-LCL
§1 DQA1*05 =
DQA1*03 1 B-LCL
§5 DQB1*03 >
DQB1*05 3.2§4
B-LCL §2 DQA1*05 >DQA1*03 2.7 B-LCL §6
DQB1*02 >
DQB1*05 4.6
B-LCL §5
DQA1*03 >
DQA1*01 3.2 B-LCL
§1 DQB1*02 =
DQB1*03 1§4
B-LCL §6
DQA1*05 >
DQA1*01 3.0 PBMC
§9
DQB1*02 >
DQB1*05 5.6§11
§17
B-LCL §7 DQA1*05 >DQA1*02 2.7 PBMC §10
DQB1*02 >
DQB1*06 5.9
PBMC
§9
DQA1*05 >
DQA1*01 4.8 PBMC
§19
DQB1*03 >
DQB1*05 3.1
§10 §21
§11 §12
§17 §15
PBMC
§12
DQA1*03 >
DQA1*01 2.9 PBMC
§13
DQB1*02 =
DQB1*03 1
§15
§19 §14
§21
PBMC
§13 DQA1*05 =
DQA1*03 1 PBMC
§16 DQB1*02 >
DQB1*03 3.3§14
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3.2. Analysis of Co-Regulated Expression of DQA1*05 and DQB1*02 mRNA
We investigated on the mechanism causing the differential expression of HLA genes associated
with T1D and CD risk by nucleofection of the full-length DQA1*05 or DQB1*02 cDNA (pDQA105 and
pDQB102) and the DQA1*05 deleted of 3′UTR (pDQA105∆) cDNA in DR1/DR3 B-LCL#5. The aim
was to verify if the ectopic expression of each alpha or beta mRNA affected the modulation of the
other mRNA. 48 h after nucleofection with pDQA105 we observed an increased surface expression of
DQα1*05 chain (Figure 2A), as expected, and an unexpected increment of DQ1β*02 chain (2,1 fold
change of MFI) expressed by endogenous gene (Figure 2B). Similarly, when we transfected the B-LCL#5
with pDQB102, we observed a 2.3-fold increase of DQ1β*02 MFI (Figure 2B) and, 1.7-fold increment of
DQα1*05 chain (Figure 2A). No variation in the MFI of DQα1*05 and DQ1β*02 was observed when we
transfected pDQA105∆ (Figure 2A,B).Cells 2019, 8, 751 9 of 14 
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transfected with empty vectors (* p < 0.05).
To assess if the overexpression of su face molecules corresponded to the increment of transcripts,
we p rformed an absolute quant fication of DQA1 and DQB1 mRNA by qPCR, using allele- pecific
primers (Table 2) at 48 h after nucleofectio . In Figure 2C, we showed the copy number of transcripts
expressed by non-transfected DR1/DR3 B-LCL#5. As already reported in [8], at a steady-state, the
amount of endogenous DQA1*05 and DQB1*02 CD-associated transcripts was 5-fold higher, in
comparison to the amount of non-CD associated DQA1*01 and DQB1*05 mRNA. Following the
nucleofection of DR1/DR3 B-LCL#5 with pDQA105, we observed a 4.7-fold increase of DQA1*05
mRNA, including ectopic and endogenous transcripts, and 5.5-fold increase of DQB1*02 endogenous
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mRNA (Figure 2D). A slight increase has been quantified also for non–T1D associated transcripts,
DQA1*01 (2,3 fold) and DQB1*05 (1,8 fold) mRNA, since they are not significant (Figure 2D). When
we transfected pDQA105∆, the cDNA deleted of 3’UTR, we did not observe any mRNA increase.
Analogously, following the transfection of pDQB102, we observed an approximate 3-fold increase in
DQA1*05 mRNA and endogenous DQB1*02 mRNA (Figure 2D), while the other transcripts showed
only a low increase.
To confirm this phenomenon, we repeated the same transfection in DR7/DR14 B-LCL lacking the
DQA1*05 allele. The ectopic expression of the pDQA105 construct induced the synthesis of DQα1*05
surface molecule (Figure 3A) and DQA1*05 mRNA (Figure 3B). Notably, we appreciated a 19.5-fold
increase in the endogenous DQB1*02 mRNA (Figure 3B). Although in a reduced amount, the DQA1*01,
DQA1*02, and DQB1*05 transcripts increased (5-, 4.9-, and 7.4-fold, respectively, Figure 3B). These
results demonstrated that the ectopic expression of a full-length DQA1*05 cDNA induced a marked
rise of DQB1*02 mRNA expression.Cells 2019, 8, 751 10 of 14 
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and nascent RNA. This cell line was transfected with pcDNA and pDQA105 constructs. In panel
A e sho the FI assessed by flow cytometry. Panel B reports the fold variation of endogenous
DQA1*01, DQA1*02, DQB1*02 and DQB1*05 mRNA. P value was calculated respect to cells transfected
with empty vector (* < 0.05). Panel C shows the quantity of nascent endogenous mRNA following
pDQA105 transfection. The left histogram shows the ectopic DQA1*05 mRNA in addition to the
end genous DQA1*01 and DQA1*02 mRNA, as percentag of total DQA1 transcript. The right
histo ram reported the amount of nascent e dogenous DQB1*02 and DQB1*05 mRNA as percent ge of
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We investigated if the overexpression of endogenous mRNA, following the nucleofection is
determined by de novo transcription. We treated DR7/DR14 B-LCL with the 5-ethynyluridine (EU)
that is incorporated into the nascent RNA. New synthetized EU-labeled RNA, is quantified by cDNA
preparation and qPCR. The results are reported in Figure 3C as the percentage of each transcript on the
100% total mRNA. We observed that the high expression of DQA1*05 mRNA with respect to DQA1*01
and DQA1*02 is mainly represented by newly synthetized mRNA (left histogram) and this transcript
induced de novo transcription of endogenous DQB1*02 (Figure 3C, right histogram). The amount of
DQA1*01, DQA1*02, and DQB1*05 mRNA was unaffected.
3.3. DR7/DR14 B-LCLs Transfected with pDQA105 Efficiently Stimulated Gluten-Specific CD4+ T Cells
We investigated whether the new synthesized DQ2.5 heterodimer, expressed following APC
transfection, was able to stimulate a CD4+ T-cell line, previously established from the intestinal biopsies
of a homozygous DR3/DR3 CD patient [14]. We stimulated T cells with autologous DR3/DR3 B-LCL#1
or with DR1/DR3 B-LCL#5 transfected with pcDNA or pDQA105 constructs, pulsed with γ-peptide.
After 48 h, we measured the INF-γ production on supernatant by ELISA. We found that CD4 T cells,
in response to DR1/DR3 B-LCL#5 transfected with pDQA105, produced a similar amount of INF-γ
(2340 pg/mL), with respect to cells transfected by pcDNA and compared to autologous DR3/DR3
B-LCL#1 (mean INF-γ: 2125 pg/mL and 1864 pg/mL, respectively, Figure 4A). Overall, these results
demonstrated that heterozygous APC, overexpressing full-length DQA1*05 cDNA, retained the same
ability to present gluten peptides and stimulate a T-cell response than homozygous APC. We next
evaluated the antigen presenting properties of DR7/DR14 B-LCL after transfection with DQA1*05
gene lacking in that cell line and we assessed the activation of the CD4+ T cells specific for DQ2.5-γ-1
peptide at 0.1 and 1 µM suboptimal concentrations. We found that the INF-γ induced by DR7/DR14
B-LCL transfected with pDQA105 (2939.7 pg/mL at 0.1, and 3859.3 pg/mL at 1 µM) are not dissimilar
to those produced in response to homozygous DR3/DR3 B-LCL #1 (2718.3 pg/mL at 0.1 and 4063.5
pg/mL at 1 µM) at both concentrations (Figure 4B). Similar results have been obtained when T cells
were stimulated with DR1/DR3 B-LCL#1 (3089.5 pg/mL at 0.1 µM, and 4482,75 pg/mL at 1 µM).
Conversely, a low cytokine production has been detected after stimulation of T cells with DR7/DR14
B-LCL transfected with empty vector (1556.9 pg/mL at 0.1 µM and 3233.98 pg/mL 1 µM), since the
DQ2.2 molecule, expressed by this APC, is able to present the gliadin antigenic peptide with low
affinity [14,15]. Overall, these data demonstrated that APC lacking the DQ2.5 molecule, presented
antigenic gliadin peptide and became capable of stimulating the gliadin-specific CD4 T cells if an
ectopic expression of DQA1*05 alleles is induced.
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Figure 4. The antigen presenting properties of B-LCLs transfected with pDQA105. The antigen
presenting capability of B-LCL pulsed with immunodominant DQ2.5-γ1 gliadin peptide were measured
by assessing the activation of intestinal CD4+ T cell line. Panel A shows the IFN-γ production by
CD4 stimulated by DR3/DR3 B-LCL#1 and DR1/DR3 B-LCL#5 transfected with pcDNA or pDQA105
constructs. Panel B shows the IFN-γ production by CD4 stimulated with DR3/DR3 B-LCL#1, DR1/DR3
B-LCL#5, and DR7/DR14 B-LCL transfected with pcDNA or pDQA105 constructs.
4. Discussion
Although the autoimmune diseases, such as celiac disease and type 1 diabetes, are polygenic
disorders, the main genetic risk factor is represented by HLA class II genes. The encoded HLA molecules
expressed on the surface of APC have a key role in presenting the self-antigens to inflammatory
CD4+ T lymphocytes. A number of experimental evidences demonstrated that the expression of these
molecules, irrespective of the nature of the antigen, influences the achievement of the HLA-peptide
complex threshold, needed for activation and proliferation of autoreactive CD4+ T cells [16,17]. We
have previously demonstrated that DQA1*05 and DQB1*02 alleles, predisposing to CD, when carried
by heterozygous APC, are differentially expressed. This marked expression of CD associated alleles in
the APC of heterozygous patients resulted in the production of high concentration of DQ2.5 molecules,
comparable to those produced in DQ2.5 homozygous cells. As a consequence, the strength of the
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gliadin-specific CD4+ T cells response is mainly dependent on the antigen dose [8]. In the present
work, we investigated HLA expression in B-LCL and PBMC from patients affected by T1D and
in patients with co-occurrence of T1D and CD. Most heterozygous subjects carried DQA1*03 and
DQB1*03 alleles encoding DQ8 molecules, a smaller group presented DQA1*05 and DQB1*02 alleles
translating in DQ2.5 heterodimer and the third group displayed all four alleles encoding DQ2.5/DQ8
molecules (Table 1). The results of mRNA quantization confirmed in T1D the phenomenon already
demonstrated in CD. Either DQA1*03 and DQA1*05 risk alleles show an expression higher than 50%
when in heterozygous with another DQA1 allele non-associated to T1D while, if the two risk alleles
are present in the same genotype, we observed a comparable expression. The high expression was
revealed also for DQB1*03 allele in LD with DQA1*03 and for DQB1*02 in LD with DQA1*05, in terms
of relative percentage.
Notably, in DQ2.5/DQ8 positive APC that carry the two risk haplotypes, we found a comparable
amount of DQA1*03 and DQA1*05, as well as that of DQB1*03 and DQB1*02 mRNA. These findings
indicate that among the risk alleles there is not an expression hierarchy and their protein products are
expressed at same level. The consistency of our observation is fulfilled when DQ2.5 haplotype is not
associated to DQ8, as we found that DQA1*05 is more abundant than DQA1*03, and DQB1*02 is more
abundant than DQB1*03. In conclusion, our findings suggested that the allele-specific transcripts have
to reach a sort of “threshold level” to mediate the self-antigen presentation, and that a precise hierarchy
of expression exists between the DQ alleles predisposing, or not, to autoimmunity. In addition, we
found that all T1D risk alleles are regulated accordingly to a mechanism responsible for increased gene
expression, that guarantees a coordinated mRNA synthesis of DQA1 and DQB1 genes mapped on the
same chromosome.
To investigate this mechanism, we used a known T cells model system that allows us to explore
also the functional aspect. Following transfection of DQA1*05 cDNA in a B-LCL expressing the
DQ2.5 molecule, we observed an increased endogenous amount of DQB1*02 mRNA, reaching the
same quantity of DQA1*05 transcripts. Differently, by transfecting pDQA105∆ we did not observe
variations, confirming the important role of 3′UTR in the modulation of transcript stability [10].
Following transfection of pDQA105 in the B-LCL not carrying DQA1*05 allele, we observed a rise
in the expression of the endogenous DQB1*02 allele (Figure 2). In conclusion, we demonstrated that
the expression of the two genes encoding the surface molecule DQ2.5 is coordinated. To investigate
whether the DQB1*02 synthesis was due to the de novo transcription, we monitored and quantified
the incorporation of EU, the uridine analog labeling the nascent RNA (Figure 3B) and demonstrated
that the stoichiometric balance between the two transcripts of risk alleles in LD is determined by a
coordinated transcription. When we modified their equilibrium by ectopic DQA1*05 expression, we
stimulated the transcription of endogenous DQB1*02 mRNA.
To explain the mRNA coordinate transcription we suggested that the chromatin, through the
formation of loop structures, arranged the promoter of alpha allele close to the promoter of beta allele
ensuring the coordination of transcription [18]. Moreover, in our previous papers, we demonstrated
that the balance of two transcripts was determined by a coordination not only of the transcription but
also of the RNA processing. We proposed that UTRs of alpha and beta transcripts are associated, just
after their synthesis, with a protein complex that guarantees a coordinate export from the nucleus and
a coordinate turnover [10].
Finally, the antigen presentation experiments confirmed that the heterozygous DR1/DR3 B cells
retains the same ability to present the gliadin antigen than homozygous DR3/DR3 B cells and that the
overexpression of DQA1*05 did not further increase the density of DQ2.5 heterodimer. This result
clearly indicated that DQ2.5 expression reaches a “plateau” and the immune response is dependent
on the dose of antigen. However in DR7/DR14 B cells expressing DQ2.2 heterodimer the ectopic
expression of DQA1*05 gene induces the new synthesis of DQ2.5 heterodimer, which is able to present
gluten antigen and to stimulate gliadin-specific CD4+ T cells.
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In conclusion, we demonstrated that the two alleles in LD, DQA1*05, and DQB1*02, encoding
the DQ2.5 molecule, and DQA1*03 and DQB1*03, encoding the DQ8 molecule, showed a balanced
expression. A coordinated transcription is probably ensured by the chromatin structure while the
binding of the protein complex with the UTRs regulated their balanced turnover [8].
Our overall findings demonstrated that, in addition to predisposing genotype, the high expression
of risk alleles is relevant in the establishment of autoimmunity. In fact, the magnitude of the T cell
activation and proliferation is related not only to the nature of epitopes but also to the amount of the
antigen-HLA class II complexes expressed on the surface of APC.
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